## **CLAIMS**

## 1. Formula (I) compounds

**(l)** 

in which:

5

10

R represents -H, -YCR5R6COX, monocyclic, bicyclic or tricyclic aryl or heteroaryl (possibly substituted by groups of the type -YCR5R6COX, halogens, nitro, hydroxy, alkyl, and alkoxy, possibly substituted by halogens), monocyclic, bicyclic or tricyclic arylalkyl or heteroarylalkyl (in which the aryl or heteroaryl are possibly substituted by groups of the type -YCR5R6COX, halogens, nitro, hydroxy, alkyl, and alkoxy, possibly substituted by halogens). The heteroaryl may possibly be charged, of the type:

15

in which the positive charge is balanced by a suitable negative counterion;

m represents 0-1

5

10

15

20

n represents 0-3; when n represents 1, R3 and R4, which may be the same or different, are selected from H or alkyl C<sub>1</sub>-C<sub>5</sub>;

when n represents 2 or 3, R3 is equal to R4 and represents H;

p represents 0-1

X represents -OH, -O-alkyl C<sub>1</sub>-C<sub>3</sub>;

R1 and R2, which may be the same or different, are selected from: -H; alkyl C<sub>1</sub>-C<sub>5</sub>; -alkoxy, possibly substituted by halogens; -phenoxy, possibly substituted by halogens, nitro, hydroxy, alkyls; -benzyloxy, possibly substituted by halogens, nitro, hydroxy, alkyls; -COX; or together with COX of general formula (I) form a cycle of the type:

R5 and R6, which may be the same or different, are selected from the groups listed for R1 and R2;

Q and Z, which may be the same or different, are selected from: NH, O, S, -NHC(O)O-, NHC(O)NH-, -NHC(O)S-, -OC(O)NH-, -NHC(S)O-, -NHC(S)NH-, -C(O)NH-;

and Y represents O, S.

2. Formula (I) compounds according to claim 1, for use in the medical field.

WO 03/059875 PCT/IT03/00011 51

- 3. Pharmaceutical composition containing as its active ingredient a formula (I) compound according to claim 1 and at least one pharmaceutically acceptable excipient and/or diluent.
- 4. Composition according to claim 3, in the form of tablets, capsules, pills, sachets, vials, powders, suppositories, solutions, suspensions, emulsions or liposomal preparations.

5

10

- 5. Composition according to claim 4, which can be administered by the enteral or parenteral routes.
- 6. Use of formula (I) compounds according to claim 1 for the preparation of a medicine for the treatment of diseases responding to PPAR $\alpha$  activation.
- 7. Use according to claim 6, in which the diseases are selected from the group consisting of heart failure, the hyperlipaemias and atherosclerosis.